As the first excimer laser platform approved by the FDA in 17 years, the Bausch + Lomb TENEO Excimer Laser Platform—approved for the treatment of myopia and myopic astigmatism—takes LASIK to another level of excellence.
An open, airy device, TENEO boasts the smallest footprint (6.8 sq. ft.) of any laser currently available in the United States. Its highly intuitive graphical user interface makes everyday use, as well as physician and staff onboarding and training, fast and easy.
With respect to ergonomics, hunching over a microscope through multiple procedures takes a toll on surgeons. TENEO’s microscope, adjustable through 360 degrees, reduces neck and shoulder strain.
Regarding patient comfort, the TENEO features a swiveling bed with a wide mattress designed to accommodate the shape of the spine and all patient sizes. The headrest is uniquely adapted to keep patients comfortable and stable.
Meeting the Need for Speed, Efficiency, and Safety
TENEO offers several novel features to increase LASIK speed, efficiency, and safety. Among them is its internal nomogram, unique among today’s excimer lasers. This eliminates the time-consuming process of preparing, evaluating, and adjusting nomograms. The internal nomogram also reduces the risk of error: Wherever calculations must be performed and input manually, there's an opportunity for transcription errors, which lead to output errors. For the first time, TENEO gives ocular surgeons the ability to treat patients based off the manifest refraction, greatly improving speed and efficiency.
In terms of safety, TENEO’s high-speed laser pulses at 500 Hz, faster than the blink of an eye. Thus, treatments are achieved with great precision at approximately 1.2 seconds per diopter, the fastest ablation time of all excimer lasers available in the United States. In addition, its eye tracker monitors the eye's position—uniquely in the Z (vertical) axis—1,740 times per second, which is more than three times faster than the laser and more than 70 times faster than a movie frame rate. Take that, Maverick.
Speeds like these go far toward calming patient fears such as, “What if my eye moves, or what if I cough or sneeze?” It’s reassuring to know the laser can instantly respond and turn itself off before any harm is done.
Excellent Outcomes
All these features combine to produce TENEO’s most important benefit: previously unachieved patient outcomes. In the clinical trials that led to FDA approval, surgeons using TENEO achieved a manifest refractive spherical equivalent of - 0.04 D at 9 months for 333 eyes treated between -1.0 D and -10.0 D with between 0 and 3.0 D of myopic astigmatism.
This translates to better vision outcomes than those with glasses or contact lenses: fewer starbursts and halos, gaining one or more lines of corrected distance, and improved contrast sensitivity and visual acuity. Relative to glasses or contacts, we have never seen improvements like these with LASIK, but now we have peer-reviewed research to support it.
We have also abundant real-world experience reflecting the research. In total thus far, we have each treated hundreds of patients using the TENEO platform with excellent results. It’s not unusual for patients to express amazement—often right out of the laser suite—at how much better they can already see.
Making game-changing advances in LASIK is extremely challenging. But these significant findings show that, relative to glasses or contact lenses, patients are more satisfied and are more likely to see better after undergoing LASIK with the Bausch + Lomb TENEO Excimer Laser Platform.
